CROSSJECT et la BARDA consolident le plan de développement pédiatrique de ZEPIZURE® selon les attentes de la FDA avec un financement renforcé jusqu’en 2030

Crossject secured an additional $4.7 million in non-dilutive BARDA funding for the FDA-recommended pediatric clinical development plan for ZEPIZURE®. The contract term was extended to June 21, 2030, bringing total BARDA funding committed to ZEPIZURE development to $48.0 million. The funding de-risks development costs and supports the program's pediatric regulatory pathway.

Analysis

The incremental government funding reduces near-term dilution risk and raises the probability that ALCJ can carry the pediatric program through protocol execution without a financing event. The market should value this primarily as an extension of the asset's risk-adjusted lifecycle, not as recurring revenue: the economic inflection remains regulatory clearance followed by procurement orders, manufacturing readiness, and evidence that public-sector demand can convert into repeatable sales.

The 2030 development horizon is a double-edged sword. It supports cash planning and signals agency engagement, but it also lengthens the period in which investors bear clinical, CMC/manufacturing, and budget-appropriation risk; absent nearer-term milestones, the equity can remain a funding-option story rather than rerate on fundamentals. A pediatric label could materially improve the strategic value of a no-needle emergency platform, particularly for stockpiling and hospital/EMS use, but commercial value depends on label breadth and procurement volumes rather than development reimbursement.

Consensus may overread government support as a proxy for FDA approval. BARDA's commitment is a strong validation of preparedness relevance, yet it does not eliminate FDA review risk or guarantee an end-market contract. The key 1-3 month catalyst is disclosure of protocol timing, enrollment feasibility, and the next FDA interaction; over 6-18 months, investors should focus on regulatory milestones, manufacturing validation, and any procurement framework rather than the headline contract value.

Key Decisions for Investors

• Maintain ALCJ as a small, event-driven long/watch position rather than a core holding until the company discloses cash runway, the pediatric study timeline, and remaining development spend. Upside requires a regulatory/procurement rerating; downside is renewed dilution if funded scope expands beyond available cash.
• Add only on confirmation of a defined FDA milestone or pediatric-study initiation, preferably after verifying adequate average daily liquidity. Avoid chasing an announcement-day move in a likely thinly traded Euronext microcap; position size should reflect gap risk and limited exit liquidity.
• Set a thesis-failure trigger around any guidance indicating delayed enrollment, expanded CMC requirements, or a need for equity financing before the next major regulatory catalyst. A material reduction in BARDA scope, failure to meet a disclosed milestone, or lack of procurement progress within 12 months would weaken the strategic-value case.
• Do not use listed options as a hedge unless liquid ALCJ contracts are demonstrably available; they are unlikely to offer efficient protection. For portfolio risk control, hedge biotech beta separately rather than shorting broad healthcare exposure against this idiosyncratic government-development catalyst.